Whalesbook
### SEBI Approves IPOs for Hindustan Labs and RK Steel
India's securities regulator has given the final go-ahead for two companies, Hindustan Laboratories and RK Steel Manufacturing Company, to launch their Initial Public Offerings (IPOs). The Securities and Exchange Board of India (SEBI) issued its approval on April 27, 2026, following initial filings in September 2025. This clears the way for both companies to list on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
### Hindustan Laboratories: Focusing on Government Contracts
Hindustan Laboratories plans an IPO with a fresh issue of 50 lakh shares and an offer for sale (OFS) of 91 lakh shares by its promoter. The company will use the capital raised primarily to boost working capital and for general corporate needs. Its business focuses on manufacturing and supplying generic medicines mainly to government institutions via a business-to-government (B2G) model. This approach means much of its revenue depends on government contracts and tender success. The Indian pharmaceutical sector expects revenue growth of 7-9% in FY2026, though growth in the US market is slowing.
### RK Steel Manufacturing: Debt Repayment Key Goal
RK Steel Manufacturing Company's IPO is structured as an entirely fresh issue of up to 2 crore equity shares. The company intends to use the funds to repay borrowings, alongside meeting working capital needs and general corporate expenses. This focus on debt repayment is important for a company in the capital-intensive steel tubes and pipes sector. The Indian steel sector is expecting a rebound in IPO activity after a slow 2025, with an estimated ₹4,000 crore potentially raised through new listings. Companies like RK Steel are increasingly focusing on strengthening their balance sheets and reducing debt.
### Market Caution Dampens IPO Sentiment
These IPO approvals come as the Indian primary market shows significant caution. Despite gains in secondary indices like the Nifty 50 and BSE Sensex, investor sentiment for new listings remains weak in April 2026. This caution stems from global economic uncertainties and the mixed performance of recent IPOs, many of which started trading at a discount in 2026. The market needs a sustained rally in major indices to fully boost the IPO pipeline. While this environment poses challenges, the distinct business models of Hindustan Laboratories (B2G pharma) and RK Steel Manufacturing (debt reduction) might appeal to investors.
### Risks for New Listings in Wary Market
Despite SEBI's approval, both companies face risks in a cautious market. Hindustan Laboratories' reliance on government contracts creates concentration risk, making revenue vulnerable to policy changes or procurement shifts. RK Steel Manufacturing operates in the cyclical steel industry, prone to price swings and stiff competition. In a market that has often punished highly-priced IPOs, both companies must show strong fundamentals and clear growth plans to gain investor trust. The trend of many 2026 IPOs showing mixed listing-day results and starting at a discount highlights higher risk for new companies.